×
About 58,604 results

ALLMedicine™ Multiple Myeloma Center

Research & Reviews  26,761 results

Carfilzomib-induced atypical haemolytic uraemic syndrome: a diagnostic challenge and th...
https://doi.org/10.1136/bcr-2020-239091
BMJ Case Reports; Darwin A, Malpica L et. al.

Feb 27th, 2021 - Haemolytic uraemic syndrome (HUS) is a thrombotic microangiopathy (TMA) that presents with renal insufficiency, thrombocytopaenia and microangiopathic haemolytic anaemia. Typical HUS is associated with Shiga toxin while atypical HUS (aHUS) is due ...

Visceral adipose tissue glucose uptake is linked to prognosis in multiple myeloma patie...
https://doi.org/10.1016/j.clnu.2021.02.010
Clinical Nutrition (Edinburgh, Scotland); da Cunha Júnior AD, Silveira MN et. al.

Feb 26th, 2021 - The use of computerized tomography to opportunistically assess body composition has highlighted abnormalities such as low muscle mass and high adiposity may be hidden conditions in cancer patients. However, the role of skeletal muscle (SM), subcut...

Development and validation of a disease risk stratification system for patients with ha...
https://doi.org/10.1016/S2352-3026(20)30394-X
The Lancet. Haematology; Shouval R, Fein JA et. al.

Feb 26th, 2021 - Diagnosis and remission status at the time of allogeneic haematopoietic stem-cell transplantation (HSCT) are the principal determinants of overall survival following transplantation. We sought to develop a contemporary disease-risk stratification ...

see more →

Guidelines  181 results

Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and fo...
https://doi.org/10.1016/j.annonc.2020.11.014
Annals of Oncology : Official Journal of the European Soc... Dimopoulos MA, Moreau P et. al.

Feb 7th, 2021 - Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.|2021|Dimopoulos MA,Moreau P,Terpos E,Mateos MV,Zweegman S,|

KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological mali...
https://doi.org/10.1016/j.kint.2020.07.012
Kidney International; Małyszko J, Bamias A et. al.

Dec 5th, 2020 - The bidirectional relationship between cancer and chronic kidney disease (CKD) is complex. Patients with cancer, particularly those with hematological malignancies such as multiple myeloma and lymphoma, are at increased risk of developing acute ki...

Expert Perspective on ASCO20 Immunotherapy Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200234/full/

Jul 1st, 2020 - CAR T-cell therapy with BCMA-targeting idecabtagene-vicleucel (ide-cel) has emerged to be a game-changer as shown by this first pivotal phase II trial of CAR T-cell therapy in multiple myeloma (MM). Ide-cel is a first-in-class BCMA-directed CAR T-...

KRd, VRd Equivalency in Multiple Myeloma ‘Reassuring’ to Hematologists
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200219/full/

Jun 23rd, 2020 - Awaited results of the ENDURANCE trial showed equivalency between a regimen of carfilzomib plus lenalidomide and dexamethasone (KRd) and bortezomib, lenalidomide, and dexamethasone (VRd) as an initial therapy for patients with standard- or interme...

see more →

Drugs  251 results see all →

Clinicaltrials.gov  29,013 results

Carfilzomib-induced atypical haemolytic uraemic syndrome: a diagnostic challenge and th...
https://doi.org/10.1136/bcr-2020-239091
BMJ Case Reports; Darwin A, Malpica L et. al.

Feb 27th, 2021 - Haemolytic uraemic syndrome (HUS) is a thrombotic microangiopathy (TMA) that presents with renal insufficiency, thrombocytopaenia and microangiopathic haemolytic anaemia. Typical HUS is associated with Shiga toxin while atypical HUS (aHUS) is due ...

Visceral adipose tissue glucose uptake is linked to prognosis in multiple myeloma patie...
https://doi.org/10.1016/j.clnu.2021.02.010
Clinical Nutrition (Edinburgh, Scotland); da Cunha Júnior AD, Silveira MN et. al.

Feb 26th, 2021 - The use of computerized tomography to opportunistically assess body composition has highlighted abnormalities such as low muscle mass and high adiposity may be hidden conditions in cancer patients. However, the role of skeletal muscle (SM), subcut...

Development and validation of a disease risk stratification system for patients with ha...
https://doi.org/10.1016/S2352-3026(20)30394-X
The Lancet. Haematology; Shouval R, Fein JA et. al.

Feb 26th, 2021 - Diagnosis and remission status at the time of allogeneic haematopoietic stem-cell transplantation (HSCT) are the principal determinants of overall survival following transplantation. We sought to develop a contemporary disease-risk stratification ...

see more →

News  2,363 results

NICE Draft Guidance Approves Lenalidomide as Maintenance Treatment for Multiple Myeloma
https://www.medscape.com/viewarticle/944919

Jan 28th, 2021 - The National Institute for Health and Care Excellence (NICE) has published draft guidance recommending lenalidomide (Revlimid, Bristol-Myers Squibb) as first maintenance treatment after an autologous stem cell transplant for newly diagnosed multip...

PharmaMar Soars 21% After Mouse Data Confirm Drug's Efficacy Against COVID
https://www.medscape.com/viewarticle/944712

Jan 26th, 2021 - MADRID (Reuters) - Shares in Spanish pharmaceutical company PharmaMar spiked over 20% on Tuesday after it cited a paper published in the journal Science that confirmed "potent preclinical efficacy" of its drug Aplidin against COVID-19. A study car...

Assessing Measurable Residual Disease Tied to Better Outcome in Multiple Myeloma
https://www.medscape.com/viewarticle/943007

Dec 21st, 2020 - NEW YORK (Reuters Health) - Clinical decision-making based on assessment of measurable residual disease (MRD) is associated with better outcome in patients with multiple myeloma (MM), a real-world study indicates. Patients who were MRD negative, a...

Durable Responses With Anti-BCMA CAR T-cell for Multiple Myeloma
https://www.medscape.com/viewarticle/942284

Dec 8th, 2020 - For patients with heavily-pretreated multiple myeloma, the early and deep responses seen with the novel chimeric antigen receptor T-cell (CAR T-cell) construct ciltacabtagene autoleucel (cilta-cel) have also been durable, according to investigator...

Five-Minute SC Injection of Daratumumab in R/R Multiple Myeloma
https://www.medscape.com/viewarticle/942222

Dec 7th, 2020 - Data from the Apollo study provide proof for the subcutaneous administration (sc) of daratumumab (Darzalex Faspro) in combination with pomalidomide (Pomalyst) and dexamethasone (Pd) for patients with relapsed or refractory multiple myeloma (RRMM)....

see more →

Patient Education  35 results see all →